Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sci PharmtechTPE:4119 +2.06%78 Debt-to-Equity is 0.20 as of Jun. 2026, which is 54% above its 10-year median of 0.13. GuruFocus rates TPE:4119 with a GF Score™ of 78/100 and a GF Value™ of NT$74.43 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 811 Drug Manufacturers companies, Sci Pharmtech ranks better than 59.8% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Sci Pharmtech's Debt-to-Equity or its related term are showing as below:
TPE:4119'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.13 Max: 0.25
Current: 0.2
During the past 13 years, the highest Debt-to-Equity Ratio of Sci Pharmtech was 0.25. The lowest was 0.00. And the median was 0.13.
TPE:4119's Debt-to-Equity is ranked better than 59.8% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs TPE:4119: 0.20
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Sci Pharmtech Debt-to-Equity Related Terms
Sci Pharmtech Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Sci Pharmtech's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sci Pharmtech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sci Pharmtech Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sci Pharmtech's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Sci Pharmtech's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sci Pharmtech (TPE:4119) has a Debt-to-Equity of 0.20 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sci Pharmtech and its competitors. This is 54% above median its historical median of 0.13. According to the industry distribution chart, Sci Pharmtech ranks #326 out of 811 companies in the Drug Manufacturers industry, placing it in the top 40.2%.
Is Sci Pharmtech's Debt-to-Equity too high?
Sci Pharmtech's current Debt-to-Equity of 0.20 is 54% above median its 10-year median of 0.13. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Sci Pharmtech's value of 0.20 is 25.9% below this industry median. Based on the distribution chart, Sci Pharmtech ranks #326 out of 811 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sci Pharmtech has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sci Pharmtech's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sci Pharmtech ranks #326 out of 811 companies for Debt-to-Equity. This puts Sci Pharmtech in the upper half of its industry. The industry median Debt-to-Equity is 0.27. Sci Pharmtech's value of 0.20 is 25.9% below this benchmark. While the company's 10-year median is 0.13 vs. the industry median of 0.27, Sci Pharmtech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sci Pharmtech's current Debt-to-Equity of 0.20 is 25.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sci Pharmtech and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sci Pharmtech's current Debt-to-Equity is 0.20, which is 54% above median its own 10-year median of 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sci Pharmtech stock overvalued right now?
Based on GuruFocus' analysis, Sci Pharmtech (TPE:4119) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$74.43, compared to a current price of NT$54.40 — trading 26.9% below its estimated fair value. The current Debt-to-Equity is 0.20, which is 54% above median its 10-year median of 0.13 and 25.9% below the Drug Manufacturers industry median of 0.27. Sci Pharmtech's overall GF Score™ is 78/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Sci Pharmtech (TPE:4119), the current Debt-to-Equity is 0.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sci Pharmtech (TPE:4119) Overvalued in 2026?
Based on GuruFocus' analysis, Sci Pharmtech stock appears to be undervalued.
The current stock price of NT$54.40 is trading 26.9% below its estimated GF Value™ of NT$74.43.
GuruFocus considers Sci Pharmtech to be Modestly Undervalued.
Key valuation signals for TPE:4119:
Debt-to-Equity: 0.20 (54% above median its 10-year median of 0.13)
GF Value™: NT$74.43 vs. price of NT$54.40 (26.9% below fair value)
Industry Position: 25.9% below the Drug Manufacturers median (#326 of 811)
No single metric tells the full story. See the TPE:4119 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sci Pharmtech Inc is engaged in the research and development, manufacture, and sales of active pharmaceutical ingredients, intermediates, and specialty chemicals. Geographically, the primary markets of the company are Italy, Germany, Japan, Taiwan, the United States, Switzerland, Spain, Belgium, Netherlands, and others.
78GF Score
Get the complete analysis for TPE:4119
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4119 has been successfully added to your 
